Senzime AB - Asset Resilience Ratio

Latest as of December 2025: 20.00%

Senzime AB (SEZI) has an Asset Resilience Ratio of 20.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Senzime AB to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr73.97 Million
≈ $7.96 Million USD Cash + Short-term Investments

Total Assets

Skr369.81 Million
≈ $39.80 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Senzime AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SEZI current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Senzime AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Senzime AB for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr73.97 Million 20.0%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr73.97 Million 20.00%

Asset Resilience Insights

  • Good Liquidity Position: Senzime AB maintains a healthy 20.00% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Senzime AB Industry Peers by Asset Resilience Ratio

Compare Senzime AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 34.37%
Stratec SE
XETRA:SBS
Medical Devices 0.29%
Shinhung
KO:004080
Medical Devices 4.17%
DRTECH Corporation
KQ:214680
Medical Devices 5.18%
Novacyt
PA:ALNOV
Medical Devices 0.02%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.48%

Annual Asset Resilience Ratio for Senzime AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Senzime AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 20.00% Skr73.97 Million
≈ $7.96 Million
Skr369.81 Million
≈ $39.80 Million
-3.77pp
2024-12-31 23.78% Skr100.94 Million
≈ $10.86 Million
Skr424.53 Million
≈ $45.69 Million
-11.05pp
2023-12-31 34.83% Skr151.01 Million
≈ $16.25 Million
Skr433.54 Million
≈ $46.66 Million
+26.76pp
2022-12-31 8.07% Skr26.04 Million
≈ $2.80 Million
Skr322.68 Million
≈ $34.73 Million
-34.81pp
2021-12-31 42.88% Skr74.87 Million
≈ $8.06 Million
Skr174.62 Million
≈ $18.79 Million
-19.04pp
2020-12-31 61.92% Skr160.31 Million
≈ $17.25 Million
Skr258.89 Million
≈ $27.86 Million
+45.47pp
2019-12-31 16.46% Skr30.90 Million
≈ $3.33 Million
Skr187.76 Million
≈ $20.21 Million
-0.11pp
2018-12-31 16.57% Skr32.67 Million
≈ $3.52 Million
Skr197.16 Million
≈ $21.22 Million
+11.31pp
2017-12-31 5.26% Skr8.74 Million
≈ $940.35K
Skr166.03 Million
≈ $17.87 Million
-1.15pp
2016-12-31 6.41% Skr10.03 Million
≈ $1.08 Million
Skr156.31 Million
≈ $16.82 Million
--
pp = percentage points

About Senzime AB

ST:SEZI Sweden Medical Devices
Market Cap
$49.06 Million
Skr455.92 Million SEK
Market Cap Rank
#22050 Global
#407 in Sweden
Share Price
Skr2.90
Change (1 day)
+0.87%
52-Week Range
Skr2.88 - Skr6.59
All Time High
Skr26.50
About

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more